Generex Biotechnology Corporation
GNBTQ
OTC PK
| 04/30/2021 | 01/31/2021 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -37.14% | 350.64% | |||
| Gross Profit | 56.86% | -261.29% | |||
| SG&A Expenses | -26.01% | -46.85% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -25.56% | -39.61% | |||
| Operating Income | 25.80% | 39.23% | |||
| Income Before Tax | 134.77% | -122.10% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 134.77% | -122.10% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | 126.13% | 26.16% | |||
| Net Income | 138.30% | -124.41% | |||
| EBIT | 25.80% | 39.23% | |||
| EBITDA | 26.59% | 39.97% | |||
| EPS Basic | 136.81% | -97.38% | |||
| Normalized Basic EPS | 138.57% | -98.83% | |||
| EPS Diluted | 80.14% | -98.56% | |||
| Normalized Diluted EPS | 131.49% | -98.83% | |||
| Average Basic Shares Outstanding | 4.07% | 13.69% | |||
| Average Diluted Shares Outstanding | 27.50% | 13.69% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
